CLINICAL
Overview
Sechrist Industries, Inc. is the trusted provider of hyperbaric chambers to physicians across the country and around the world. In fact, Sechrist has sold more than three times the number of hyperbaric oxygen chambers installed in the US than all the other manufacturers combined. At Sechrist, we continue to develop and evolve our comprehensive line of monoplace hyperbaric oxygen chambers and educate the world of the benefits of hyperbaric medicine. At Sechrist Industries, our goal is to help physicians and clinicians around the world bring hyperbaric oxygen medicine to all those in their community who can benefit from this vital treatment.
Sechrist Industries, Inc. has designed hyperbaric chambers for over 35 years with the highest level of safety standards. All Sechrist monoplace hyperbaric chambers are meticulously designed and manufactured down to the finest detail. Every part and process is thoroughly validated and tested over the entire production system before leaving the Sechrist manufacturing facility. Sechrist Industries follows the most stringent of processes and procedures thus creating the highest quality and highest reliability hyperbaric chamber on the market. The cylinders of Sechrist Industries’ hyperbaric oxygen chambers are all fabricated of polished acrylic that meets the Safety Standard for Pressure Vessels for Human Occupancy. Please click the images below for a more detailed description of each of Sechrist ‘s high quality monoplace hyperbaric oxygen chambers.
Models
Sechrist H-Series
The Sechrist 3300H, 3600H, and the largest 4100H are the newest hybrid pneumatic hyperbaric oxygen chambers. The new model H chamber integrates all the best features of all past chamber models. Not only does the H chamber include the revolutionary oxygen conservation system, it also includes the reliability of the pneumatic control system and a unique shut off safety system which allows two emergency shut-off modes. With chambers in over 100 countries and the highest quality and reliability of any hyperbaric chamber on the market, the 3300H, 3600H, and 4100H will be the top clinical choice in the international market.
The Sechrist pneumatic hyperbaric chambers are offered four uniquely designed models. As with all Sechrist chambers, each chamber is designed and monitored thru the entire manufacturing process for the highest safety and reliability rating of any hyperbaric oxygen chamber on the market.
Sechrist H-Series with Gurney storage and Low Profile Gurney
- GURNEY STORAGE FEATURE - The H-Series Hyperbaric Oxygen Chambers are the advanced and convenient chambers on the market. With the new space-saving gurney storage the hospitals and clinics now have the ability to store the gurney under the hyperbaric chamber. This convenient storage allows for additional free space in any hyperbaric treatment room thus eliminating the additional space needed to store the free standing chamber gurneys. The low profile gurney lowers to 23" from the floor to the top of mattress. This new low profile gurney design cuts a full 5" off the high of a standard gurney. The new low profile hyperbaric gurney allows for an easier and safer access of the patient to the gurney.
- FIRST IN PATIENT CARE - The H-Series Hyperbaric Oxygen Chambers are available in three spacious interior diameters - 33", 36", and the 41". All Sechrist Hyperbaric Chambers provide the ability for the patient to rest in a reclined or angled postiion for better comfort. The H-Series Hyperbaric Chamber system allows connection with a fully integrated entertainment system that allows the patient to watch television, watch movies, or just listen to music on thier MP3 player. All Sechrist Monoplace Hyperbaric Chambers are equiped with dual spreakers to provide optimal listening pleasure. The low profile hydraulic gurney provides for easy loading of the patient into the chamber without additional transfers. Within a Sechrist hyperbaric chamber bariatric patients up to 700 lbs can be comfortably treated.
3600H Chamber Overview
Features
Assuring safety
Sechrist Hyperbaric Oxygen Chambers are designed and tested to provide the most complete safety specific monoplace hyperbaric chamber on the market. All Sechrist hyperbaric chambers go through a thorough inspection and safety process that is monitored and maintained throughout the manufacturing process. Sechrist hyperbaric oxygen chambers are the only monoplace hyperbaric chambers that are fully manufactured and tested in the USA in our state-of-the-art facility.
The H-Series Hyperbaric Oxygen Chambers is the only monoplace hyperbaric system that provides two emergency vent modes. The Standard Emergency Vent system decompresses in less than 120 seconds, and can be controlled by a technician to allow control of the descent and to optimize for patient comfort. The H-Series Hyperbaric System also includes an Emergency Shut-off and Automatic Vent System for full decompression within 120 seconds without the need of an attendant.
Increasing efficiency
The Sechrist H-Series hyperbaric oxygen chambers are all equiped with the necessary monitors and controls to accept electronic data collection modules. With precision controls and easy viewing displays the Sechist H-Series Hyperbaric Chambers are easy to use and adjust by the attending pysician or technician. All Sechrist oxygen chambers have easily accessible ventilation controls for the adjustment of gas flow through the chamber for complete oxygen conservation. Sechrist’ s Oxygen Conservation Mode significantly reduces the amount of oxygen consumed during a treatment.
Supporting critical care
The Sechrist H-Series Hyperbaric Chamber also provides for respiratory support that automatically compensates for the pressure changes in the chamber using Sechrist’ s customized hyperbaric ventilator. The Sechrist Hyperbaric Ventilator is designed and manufactured by Sechrist and is the only true hyperbaric ventilator on the market for Sechrist chambers. The Sechrist H-Series Hyperbaric Chamber also accommodates multiple connection types for full support of a patients critical needs:
- Multiple intravenous transfusion lines.
- Electrical monitoring including EKG, temperature and blood pressure.
- Transcutaneous oxygen monitoring.
- Patient air-break breathing system.
Indications
Evidence-based indications accepted by the UHMS, approved by Medicare
Elective – Chronic Indications
Emergent/Urgent – Acute Indications
Evidence-based indications accepted by the UHMS, NOT approved by Medicare
Elective – Chronic Indications
Emergent/Urgent – Acute Indications
Contraindications
The only absolute contraindication to hyperbaric oxygen therapy is an untreated pneumothorax due to the risk of gas emboli, tension pneumothorax and pneumomediastinum
The following contraindications are relative but should be carefully considered when weighing the risk benefit ratio for HBO. [1]
- Bleomycin- The primary dose-limiting toxicity of bleomycin is the development of pulmonary toxicity ranging from radiographic changes to pneumonitis to fatal pulmonary fibrosis. Despite the theoretical risk, no documented cases of bleomycin pulmonary toxicity from hyperbaric oxygen exist. It is felt that as long as the patient has no signs of pulmonary compromise from fibrosis, and it has been over three months since he or she was treated with bleomycin, his or her exposure to bleomycin should not be a health factor.
- Doxirubicin- An anteneoplastic agent that exerts its effect through generation of free radicals and has a dose-limiting cardiac toxicity as a consequence of therapy. HBOT and doxorubicin should be avoided in combination. It is recommended that at least three days to elapse between the last doxirubicin dose and the initiation of a course of HBOT.
- Cisplatin- A chemotherapeutic that interferes with the DNA synthesis, affecting fibroblast production and collagen synthesis. HBOT may impede wound healing in combination with cisplatin. Any patient who has a wound healing problem should not be treated concomitantly. However, in life threatening situations such as CO poisoning, gas gangrene and necrotizing fasciitis, wound healing concerns are overridden by the emergency indication.
- Disulfiram- A theoretical risk with using disulfiram in the chamber is that it, or its reduced metabolite diethyldithiocarbamate, blocks the production of superoxide dismutase (SOD), a major protective enzyme against oxygen toxicity.
- Mafenide Acetate (Sulfamylon)- An antimicrobial agent used in burn patients is a carbonic anhydrase inhibitor and tends to promote CO2 retention and vasodilation which can lower the seizure threshold.
- Upper Respiratory Infections or Chronic Sinusitis- May pose the inability to equalize middle-ear pressure
- Emphysema with C02 retention or Asthma- These obstructive diseases can reduce the outflow of gas during decompression leading to pulmonary barotrauma.
Risks and Complications
Risk benefit ratio in favor of offering hyperbaric oxygen therapy, example statement:
"The patient was informed of the possible risks and complications of hyperbaric oxygen therapy. These include, but are not limited to, fire, barotrauma of the ears, sinuses, and lungs to include air embolism, central nervous system oxygen toxicity resulting in seizure, cataracts, myopia, and exacerbation of congestive heart failure. Having no absolute contraindication to hyperbaric oxygen therapy the patient will be offered treatment at 2.0 ATA for 90 minutes. Twenty treatments will initially be provided on a once daily basis Monday through Friday. Thereafter, a re-evaluation of the patient’s clinical progress will be in order to determine if additional treatments may be required."
FDA
Sechrist hyperbaric chambers have been cleared by the FDA 510K .
Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Dmg, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRI-1 does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
Prescription
• A Physician order is required for the delivery of Hyperbaric Oxygen therapy and must include:
- Hyperbaric diagnosis and Treatment protocol.
- Specific pre-HBOT diagnostics necessary
- Date on which HBOT is to begin
- Treatment Pressure (depth) and oxygen breathing period (dive profile that is to be used)
- Air breaks – when indicated or per treatment protocol
- TCOM’s (as appropriate to patient condition)
- Total treatments.
• At a minimum, the following elements should be provided on the physician order form as well:
- The date of the order
- The patients name, date of birth and medical record/account number.
- The name of physician or authorized individual ordering hyperbaric oxygen services.
- Authentication of physician or authorized individual ordering hyperbaric oxygen services.
- Orders from Physicians that are not institutionally credentialed as a qualified Hyperbaric provider will not be accepted.
See HBO Physician Orders Overview
TECHNICAL RESOURCES
PATIENT EDUCATION FOR CLINICIANS
Related Patient Education materials:
CODING, COVERAGE AND REIMBURSEMENT
Medicare Policies & Guidelines (NCDs, LCDs, Articles)
ICD-10 that support medical necessity
CMS QUALITY MEASURES
Below are measures that are specific to Hyperbaric Oxygen Therapy. The quality measures have been issued by the US Wound Registry. For more information please see uswoundregistry.com
|
QCDR
|
Title
|
Description
|
ID
|
Measure Type
|
|
US Wound Registry (USWR)
|
Appropriate Use of Hyperbaric Oxygen Therapy for Patients with Diabetic Foot Ulcers
|
Percentage diabetic foot ulcers that received hyperbaric oxygen therapy (HBOT) appropriately.
|
443
|
Process
|
| US Wound Registry (USWR) |
Blood Glucose Check Prior to Hyperbaric Oxygen Therapy Treatment |
Percentage of HBOT treatments of patients aged 18 years and older who had their blood glucose level assessed prior to undergoing hyperbaric oxygen therapy |
446 |
Process |
| US Wound Registry (USWR) |
Major Amputation in Wagner Grade 3, 4, or 5 Diabetic Foot Ulcers Treated with HBOT |
Percentage of ulcers of patients aged 18 years or older with a diagnosis of a Wagner Grade 3, 4, or 5 diabetic foot ulcer (DFU) whose ulcer has an outcome of major amputation 6 months after completion of a course of HBOT, stratified by the Wound Healing Index |
448 |
Outcome |
MANUFACTURER
Sechrist Industries
4225 E La Palma Ave
SechristUSA.com
Anaheim, CA 92807
Phone: 1-800-SECHRIST (732-4747)
Official reprint from WoundReference® woundreference.com ©2024 Wound Reference, Inc. All Rights Reserved
NOTE: This is a controlled document. This document is not a substitute for proper training, experience, and exercising of professional judgment. While every effort has been made to ensure the accuracy of the contents, neither the authors nor the Wound Reference, Inc. give any guarantee as to the accuracy of the information contained in them nor accept any liability, with respect to loss, damage, injury or expense arising from any such errors or omissions in the contents of the work.
